P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
P19：复发难治性多发性骨髓瘤患者接受 BCMA 靶向 CAR-T 细胞疗法 IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) 治疗后完全缓解的基线相关因素：KARMMA 试验的亚组分析
期刊:Journal of Cataract and Refractive Surgery
影响因子:3.2
doi:10.1097/j.jcrs.0000000000001780
Tan, John M; Manda, Sahita I; Gill, Manjot K; Palmer, David J; Lema, Gareth M C; Maini, Rohan; Noel, Jacob; O'Malley, Grenye; Byrne, Barry J; Flotte, Terence R; Herzog, Roland W; Srivastava, Arun; Rodríguez-Otero, P; Shah, N; Munshi, N; Berdeja, J; Jagannath, S; Finney, O; Martin, N; Agarwal, A; Rowe, E; Campbell, T; San-Miguel, J
